Physician profile
James Shen
NPI 1063792265
$11,875.64
in general payments reported to CMS, 2019-2025
28 companies · $98.62 in 2025
The $98.62 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,266 · 2020: $160 · 2021: $3,557 · 2022: $284 · 2023: $34.86 · 2024: $475 · 2025: $98.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $200 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200 · Food and Beverage: $152 · Education: $56.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $200.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
| Food and Beverage | $152.13 |
| Education | $56.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $8,934.72 | 2019-2024 | Enhertu |
| Amgen INC. | $417.88 | 2019-2022 | |
| Janssen Biotech, INC. | $331.91 | 2019-2020 | |
| Astellas Pharma US INC | $251.83 | 2019-2020 | |
| Novocure Gmbh | $250.00 | 2022 | |
| Genzyme Corporation | $220.93 | 2019-2024 | |
| Sobi, INC | $200.00 | 2024 | |
| Genentech USA, INC. | $181.22 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $151.35 | 2019-2021 | |
| Puma Biotechnology, INC. | $124.95 | 2019 | |
| Seagen INC. | $99.95 | 2019 | |
| Merck Sharp & Dohme LLC | $95.84 | 2019 | |
| Dendreon Pharmaceuticals LLC | $88.51 | 2021-2025 | Provenge |
| Novartis Pharmaceuticals Corporation | $73.32 | 2019-2025 | |
| Celgene Corporation | $69.99 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $68.14 | 2019-2023 | |
| Morphosys, US INC. | $44.57 | 2021 | |
| Incyte Corporation | $41.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $38.83 | 2019-2024 | |
| Gilead Sciences, INC. | $37.09 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $31.05 | 2024 | Libtayo |
| Exelixis INC. | $30.60 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.12 | 2019 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Array Biopharma INC | $18.43 | 2019 | |
| Eisai INC. | $15.99 | 2019 | |
| Rigel Pharmaceuticals, INC. | $11.81 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Shen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.